Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Levy on the Importance of Testing for KRAS Mutations in Lung Cancer

March 18th 2021

Benjamin P. Levy, MD, discusses the importance of testing for KRAS mutations in lung cancer.

Santos Spotlights Success With Checkpoint Inhibition in Frontline Metastatic NSCLC

March 18th 2021

Edgardo Santos, MD, FACP, discusses advances made with immunotherapy regimens in the first-line treatment of patients with metastatic non–small cell lung cancer and areas of active investigation.

Dr. Spira on the Role of Broad Molecular Testing in Lung Cancer

March 17th 2021

Alexander Spira, MD, PhD, FACP, discusses the role of broad molecular testing in lung cancer.

Spira Spotlights Sotorasib and Targeting KRAS Mutations in NSCLC

March 15th 2021

Dr. Spira discusses the historical challenges of targeting KRAS, key findings from the phase 2 CodeBreaK 100 trial with sotorasib in KRAS G12C-mutant solid tumors, and the next steps of development for KRAS inhibitors in oncology.

Selpercatinib and Pralsetinib Generate Enthusiasm in RET Fusion+ NSCLC

March 15th 2021

Janakiraman Subramanian, MD, discusses the depth and durability of responses that have been reported with selpercatinib and pralsetinib, as well as ongoing research focused on improving outcomes and overcoming resistance mechanisms in RET fusion–positive NSCLC.

Osimertinib Continues to Enhance Outcomes in EGFR+ NSCLC

March 12th 2021

Lara A. Kujtan, MD, discusses the data that support the current utility of osimertinib in EGFR-mutant NSCLC and where else it is currently being explored.

FDA Will Reassess 6 Immunotherapy Accelerated Approvals

March 12th 2021

Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.

FDA Grants Fast Track Status to Poziotinib for HER2 Exon 20–Mutated NSCLC

March 11th 2021

The FDA has granted a fast track designation to poziotinib for use in previously treated patients with HER2 exon 20 mutations.

Levy Lauds Biomarker-Driven Data in Lung Cancer

March 11th 2021

Dr. Levy discusses key research efforts with targeted therapies for patients with lung cancer who harbor NTRK, KRAS, and HER2 aberrations.

Agents Targeting MET, RET, and Previously “Undruggable” KRAS Advance Treatment in NSCLC

March 11th 2021

Melissa L. Johnson, MD, discusses the implications of recent advances made in the development of oncogenetargeted agents in non–small cell lung cancer.

Chasing Survival Benefit With Novel Systemic Strategies in Early-Stage NSCLC

March 11th 2021

Kaushal Parikh, MD, MBBS, highlights ongoing research exploring systemic approaches in early-stage non¬–small cell lung cancer and shares where future efforts are headed.

Dr. Longshore on Key Molecular Markers in Metastatic Lung Cancer

March 10th 2021

John Longshore, PhD, FACMG, discusses key molecular markers in metastatic lung cancer.

Dr. Boyle on the Role of Concurrent Molecular Testing in Lung Cancer

March 10th 2021

Theresa Boyle, MD, PhD, discusses the role of concurrent molecular testing in lung cancer.

Second- or Third-Line Canakinumab/Docetaxel Fails to Significantly Improve OS in NSCLC

March 9th 2021

The combination of canakinumab plus docetaxel failed to significantly improve overall survival in patients with locally advanced or metastatic non–small cell lung cancer whose disease has progressed while on, or after, prior platinum-based chemotherapy and a PD-L1 agent, missing the primary end point of the phase 3 CANOPY-2 trial.

FDA Approves Companion Diagnostic for Lorlatinib in ALK+ NSCLC

March 9th 2021

The FDA has approved the VENTANA ALK CDx assay as a companion diagnostic to identify patients with ALK-positive non–small cell lung cancer who are eligible to receive treatment with lorlatinib.

WCLC Updates in Small Cell Lung Cancer

March 5th 2021

Panelists provide first impressions on recent clinical trials in the treatment of small cell lung cancer and comment on the safety and efficacy of study treatments.

WCLC Updates in Locally Advanced NSCLC

March 5th 2021

Key opinion leaders provide insights on chemotherapy and radiotherapy in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC).

WCLC Updates in Neoadjuvant Therapy for NSCLC

March 5th 2021

Experts in thoracic oncology discuss the role of single-agent immunotherapy as neoadjuvant therapy and comment on the viability of MPR [major pathologic response] as a surrogate endpoint for non–small cell lung cancer (NSCLC).

Poziotinib Shows Meaningful Activity in EGFR Exon 20–Mutant NSCLC

March 4th 2021

Poziotinib, when given at a daily dose of 16 mg, was found to demonstrate clinically meaningful activity when used in treatment-naïve patients with metastatic non–small cell lung cancer who harbor EGFR exon 20 mutations.

Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC

March 4th 2021

John V. Heymach, MD, PhD, discusses the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.